Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 7/20 | 0.55 |
| ▸ | AURKB | Q96GD4 | 6/20 | 0.50 |
| ▸ | CSF1R | P07333 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
| ▸ | KIT | P10721 | 1/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 5/20 | 0.45 |
| ▸ | SNCA | P37840 | 1/20 | 0.40 |
| ▸ | CHUK | O15111 | 1/20 | 0.40 |
| ▸ | ICOSLG | O75144 | 1/20 | 0.40 |
| ▸ | ICOS | Q9Y6W8 | 1/20 | 0.40 |
| ▸ | TTK | P33981 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4152214 | 1.00 | AURKA (0.55) | AURKAAURKBCSF1RPDGFRBKIT | |
| SCHEMBL5034281 | 0.86 | AURKA (0.49) | AURKAAURKBCSF1RPDGFRBKIT | |
| SCHEMBL5034290 | 0.86 | AURKA (0.49) | AURKAAURKBCSF1RPDGFRBKIT | |
| SCHEMBL6426328 | 0.85 | SNCA (0.58) | AURKAAURKBCSF1RPDGFRBKIT | |
| SCHEMBL4149448 | 0.84 | AURKA (0.60) | AURKAAURKBCSF1RPDGFRBKIT | |
| SCHEMBL4149451 | 0.84 | AURKA (0.60) | AURKAAURKBCSF1RPDGFRBKIT | |
| SCHEMBL27604791 | 0.83 | AURKA (0.53) | AURKAAURKBCSF1RPDGFRBKIT | |
| SCHEMBL4137016 | 0.83 | AURKA (0.58) | AURKAAURKBCSF1RPDGFRBKIT | |
| SCHEMBL4137009 | 0.83 | AURKA (0.58) | AURKAAURKBCSF1RPDGFRBKIT | |
| SCHEMBL4146342 | 0.83 | AURKA (0.52) | AURKAAURKBCSF1RPDGFRBKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054397-A1 | PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND | OHI NORIHITO | 2009-02-26 | — | — | US | disclosed |
| US-7429609-B2 | Pyrazole compound and medicinal composition containing the same | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-09-30 | — | — | US | disclosed |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-24 | — | — | US | disclosed |
| US-20050208582-A1 | Pyrazole compounds and pharmaceutical compositions comprising the compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-09-22 | — | — | US | disclosed |
| CN-1656079-A | Pyrazole compounds and pharmaceutical compositions containing the same | EISAI CO LTD (JP) | 2005-08-17 | — | — | CN | disclosed |
| EP-1510516-A1 | PYRAZOLE COMPOUND AND MEDICINAL COMPOSITION CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2005-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054397-A1 | PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND | CNKSR1, NR3C2, CSNK2B | AURKA 726/4885AURKB 608/4885CSF1R 1467/4885 |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | CNKSR1, NR3C2, CSNK2B | AURKA 710/4885AURKB 579/4885CSF1R 1253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.